Navigation Links
BMEYE B.V. Completes EUR 6 Million Series B Financing Round
Date:10/8/2009

AMSTERDAM, October 8 /PRNewswire/ -- BMEYE B.V., the non-invasive cardiovascular monitoring company, today announced the successful completion of its Series B financing round, raising EUR 6 million. New investors Earlybird, who led this round, and 360 Capital Partners participated in the financing, along with other existing BMEYE shareholders as LSP (Life Sciences Partners) and Techfund.

BMEYE has successfully been selling Nexfin(TM), an FDA and CE approved cardiovascular monitor which uses an easy to apply finger sensor to produce accurate beat-to-beat, non-invasive blood pressure and cardiac output data displayed on an intuitive touch screen. Proceeds from the financing will support the accelerated growth program of the company based on further product introductions and development of the sales channel.

"We are pleased to have completed this financing round, especially given today's challenging economic climate," said Rob de Ree, BMEYE's Chief Executive Officer. "This is a solid recognition of the quality of the BMEYE team and our success since the introduction of the Nexfin monitor, with highly regarded new and existing investors participating."

"We never experienced such positive response by potential customers in our Due Diligence work. BMEYE introduced truly a breakthrough technology in non-invasive, beat-to-beat cardiovascular monitoring in Europe and the United States," comments Thom Rasche, Partner at Earlybird, who will resume a board seat. "The technology is clinically validated, widely published and the market potential is very large. The main application areas are in the fast-growing segments of cardiology, emergency and critical care," adds Diana Saraceni, Partner at 360 Capital Partners who will as well resume a board position.

BMEYE B.V. was founded in 2005. In 2006 the company closed the Series A round with LSP as the lead investor.

"Over the past 3 years, BMEYE has developed from an R&D based group to a fully commercial, professional organization," says Rene Kuijten, LSP's board member. "With the addition of two qualified investors and EUR 6 million in new equity funding, the company is well equipped to continue its growth path."

About BMEYE B.V.

Mission: BMEYE B.V. is the premier provider and will set the standard of non-invasive, beat-to-beat, user-friendly cardiovascular monitoring systems, to improve patient care and reduce healthcare costs.

BMEYE B.V., a Dutch-based company in Amsterdam, develops and markets innovative medical technology with broad applications in a variety of clinical settings. The focus of BMEYE B.V. is on user friendly, non-invasive hemodynamic cardiovascular monitoring. The Nexfin(TM) family of monitors use an easy to apply finger sensor to produce accurate beat-to-beat, non-invasive blood pressure and cardiac output data displayed on an intuitive touch screen.

Patents pending. For more information please check our website at http://www.bmeye.com.

About Earlybird

Earlybird Venture Capital is one of the most successful European venture investors. Currently, Earlybird manages over 400 million Euros of assets for an international investor base. Earlybird invests in innovative, fast growing companies with outstanding management teams and high growth potential on international markets. Earlybird's portfolio currently includes more than 25 companies in seven countries (Austria, Germany, Italy, Netherlands, Switzerland, UK and USA). Since inception Earlybird has invested in 58 companies. Besides several successful trade sales, Earlybird has led six companies to an IPO at four different European exchanges.

Further information is available at http://www.earlybird.com or follow us on Twitter: EarlybirdVC

About 360 Capital Partners

360 Capital Partners is a Venture Capital firm, investing in Innovation at full scale, in Europe. 360 Capital Partners is managed by a consolidated team which has cumulated 50+ years of Venture Capital experience in investing in, following-up and/or exiting from over 60 companies and which have more than EUR200 million under management, provided by top tier international investors. 360 Capital Partners leverages an important international network, it co-invested with major international Venture Capital funds in 10 countries and have proven a top quartile track record as individuals and as a team in very different economic environments

About LSP

LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced life-science investors.

Further information is available at http://www.lspvc.com.

SOURCE BMEYE B.V.


'/>"/>
SOURCE BMEYE B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
2. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
3. Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
4. PDL BioPharma Completes October 1 Special Dividend Payment
5. SyntheMed Completes $1.0 Million Equity Placement
6. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
7. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
8. ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimers disease clinical trials
9. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
10. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
11. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging Inc. ... Ltd. (ASX: PME), has announced that the American College ... (UF) have selected the Visage 7 Enterprise Imaging ... the Emergent/Critical Care Imaging SIMulation (SIM). SIM is ... Imaging Program (WIDI), a multi-faceted and fully-integrated online ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ... company developing novel, clinical-stage therapies for sickle cell disease ... underwritten public offering of 29,090,910 units at a price ... consists of one share of the Company,s common stock ... Company,s common stock at an exercise price of $0.42 ...
(Date:2/10/2016)... Antibacterial Drugs Market - Global Industry ... ", reveals that the global antibacterial drugs market is forecast ... owing to patent expiries of blockbuster drugs. Even though the ... forecast period, the value is anticipated to decline from US$43.9 ... Antibacterial Drugs Market - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... it will attend the Ohio Safety Congress and Expo event March 9-11, 2016. ... the Greater Columbus Convention Center. , As the longest running and largest ...
Breaking Medicine News(10 mins):